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Aims The aim of this study was to evaluate the effect of hormone replacement therapy (HRT) on coronary vasomotor
function in post-menopausal women (PM) with medically treated cardiovascular risk factors (RFs) in a cross-sectional
and a longitudinal follow-up (FU) study.
Methods
and results
Myocardial blood flow (MBF) response to cold pressor testing (CPT) and during pharmacologically induced hyper-
aemia was measured with positron emission tomography in pre-menopausal women (CON), in PM with HRT and
without HRT, and repeated in PM after a mean FU of 24+14 months. When compared with CON at baseline,
the endothelium-related change in MBF (DMBF) to CPT progressively declined in PM with HRT and without
HRT (0.35+ 0.23 vs. 0.24+0.20 and 0.16+ 0.12 mL/g/min; P ¼ 0.171 and P ¼ 0.021). In PM without HRT and in
those with HRT at baseline but with discontinuation of HRT during FU, the endothelium-related DMBF to
CPT was significantly less at FU than at baseline (0.05+0.19 vs. 0.16+0.12 and 20.03+0.14 vs.
0.25+ 0.18 mL/g/min; P ¼ 0.023 and P ¼ 0.001), whereas no significant change was observed in PM with HRT
(0.19+0.22 vs. 0.23+ 0.22 mL/g/min; P ¼ 0.453). Impaired hyperaemic MBFs when compared with CON were
not significantly altered from those at baseline exam.
Conclusion Long-term administration of oestrogen may contribute to maintain endothelium-dependent coronary function in PM
with medically treated cardiovascular RFs.
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Introduction
Women with early menopause are at increased risk of developing
cardiovascular disease.1 The exact mechanisms underlying the
increased risk in developing cardiovascular disease in post-
menopausal women (PM) remain poorly understood. Post-
menopausal women commonly present higher total cholesterol,
LDL cholesterol, triglycerides, and lower HDL levels as well as
increases in body weight and arterial hypertension.1 The latter
changes in cardiovascular risk profile, which may accompany the
menopause, have been suggested as underlying mechanism for
the increased manifestation of cardiovascular disease.2 Deprivation
of endogenous atheroprotective oestrogen can be assumed as
another important cause for the increased risk for cardiovascular
disease in PM.2 Observational studies1,3 have demonstrated a
lower cardiovascular event rate in PM, who were on hormone
replacement therapy (HRT), than in those without HRT. Results
of the use of HRT with oestrogen to improve the cardiovascular
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clinical outcome in PM, however, are rather conflicting.1,4,5 The
latter disconsonant findings may be reconciled by the emerging
‘timing hypothesis’ for HRT, which favours the concept, that ben-
eficial effects of HRT in preventing the coronary atherosclerotic
process may only manifest, when HRT is commenced in younger
PM (50–59 years old) or within 10 years after menopause.2,4
The latter concept, however, has also been challenged by an
observational cohort study in PM.6 As it was observed, overall
there was no association between HRT and the occurrence of
myocardial infarction, whereas an increased risk of myocardial
infarction was noted in a subgroup of younger women between
51 and 54 years of age.6
The normal function of the vascular endothelium exerts numer-
ous nitric-oxide mediated antiatherosclerotic and antithrombotic
effects, while a dysfunctional endothelium predisposes to the
development of coronary artery disease (CAD) and future cardio-
vascular events.7 Previous investigations from our institution8 have
demonstrated that long-term HRT restored endothelial function of
the coronary arteriolar vessels in PM without coronary risk factors
(RFs), while it was not observed in those PM with RFs. Given that
medical treatment of coronary RFs, i.e. with statins or angiotensin-
converting enzyme inhibitors, commonly improves endothelium-
dependent vasomotor dysfunction,7 it remains uncertain whether
HRT in PM with medically treated RFs might still exert an
additional beneficial effect on coronary vasomotor function.
Accordingly, we aimed to evaluate the effect of long-term HRT
on vasomotor function of the coronary microcirculation in PM
with medically treated RFs in an observational cross-sectional
and a longitudinal follow-up (FU) study.
Methods
Study design
In a prospective, observational cross-sectional baseline and longitudinal
FU study, vasomotor function of the coronary microcirculation was
assessed by measuring myocardial blood flow (MBF) with positron
emission tomography (PET) at rest, and its responses to sympathetic
stimulation with cold pressor testing (CPT), and during pharmacologic
vasodilation in 48 PM (Table 1). Post-menopausal women and 12
healthy pre-menopausal women had been recruited by flyers and
newspaper advertisement. Among 53 PM with medically treated cardi-
ovascular RFs who underwent PET baseline examination, 48 repeated
the PET exam for the observational FU study. Thus, there were five
dropouts in the FU exams and these were not included in the final
analysis. For the cross-sectional baseline analysis, PET-measured
MBFs of 12 healthy pre-menopausal women served as reference to
define the range of normal coronary vasomotor function, and they
were compared with both groups of PM with and without HRT
(Table 1). For the longitudinal observational FU study, MBF measure-
ments were repeated in all PM after an FU period of at least 12
months (median FU: 22 months and inter-quartile range, IQR: 14–
28 months) (Table 2). All vasoactive medications such calcium
channel blockers, ACE inhibitors, long-acting nitrates, or b-adrenergic
blockers were withheld for at least 48 h prior to the PET studies. PM
were followed-up prospectively by the status of HRT at baseline. In the
group with HRT, however, eight women discontinued HRT during the
observational FU as they became aware of the concomitant minor risk
for breast cancer. In addition, another four women decided to drop
HRT during the FU due to the controversy about a possible increased
risk for cardiovascular events owing to HRT. Consequently, PM were
finally subgrouped according to the HRT status both at baseline and
FU: Group 1 (n ¼ 18) on HRT at both baseline and FU, Group 2
without HRT (n ¼ 18) at baseline and FU, and Group 3 on HRT at
baseline but not at FU (n ¼ 12) (Table 2). The study was approved
by the UCLA Institutional Review Board, and each participant signed
the approved informed consent form.
Study population
All study participants underwent an initial screening visit before base-
line PET study that included a physical examination, electrocardiogram
(ECG) blood pressure measurements, and routine blood chemistry.
Furthermore, study applicants were recruited, if they were without a
history of variant angina, clinically manifest cardiovascular, or any
other disease. All were normal on physical examination and had
normal resting ECGs. Women on HRT were recruited for study
purpose, if they had cessation of menses for 1 year and used HRT
for 6 months (Group 1 and Group 3). In addition, women not on
HRT qualified for the study purpose if their serum oestradiol levels
were ,20 pg/mL, oestrone ,4 ng/dL, and if menses had ceased for
1 year (Group 2). At baseline and FU study, in Group 1, seven
women were taking orally oestrogen alone and 11 were taking oestro-
gen plus a progesterone [10 received medroxyprogesterone acetate
(MPA) and 1 received micronized progesterone] at baseline and FU.
In Group 3, nine women were taking orally oestrogen alone and
three were taking oestrogen plus a progesterone (three received
MPA and none received micronized progesterone) at baseline but,
as indicated above, not any more at FU. Hormone replacement
therapy regimen in PM was installed previously by the treating gynae-
cologist before study participants were recruited for the study.
Further, concomitant preventive medical therapy for RFs (Table 3)
was taken continuously by PM (no gaps in the medication .7 days).
In the current study population, long-term use of HRT was defined
as at least 3 years of HRT before the baseline PET exam (median
period: 6 years, IQR 5–9). According to the observational study pro-
tocol, the HRT regimens were not altered throughout the FU period.
Quantification of myocardial blood flow with
positron emission tomography
Myocardial perfusion was determined with 13N-ammonia and positron
emission tomography (PET; ECAT EXACT HRþ; CTI/Siemens,
Knoxville, TN, USA).9 The relative distribution of MBF was evaluated
visually on reoriented short- and long-axis myocardial slices and semi-
quantitatively on the corresponding polar map from the last static
15 min transaxial image. All study participants revealed normal homo-
geneous 13N-ammonia tracer uptake at rest and during vasomotor
stress. Further, MBF was quantified in mL/g/min with 13N-ammonia
serial image acquisition (12 frames of 10 s each, 2 frames of 30 s, 1
frame of 60 s, and 1 frame of 900 s) by PET as described previously.9
Measurements were performed first at rest, then during CPT (reflect-
ing predominantly endothelium-dependent vasomotion) and during
pharmacologically induced hyperaemia with standard infusion of ade-
nosine or dipyridamole (140 mg/kg/min) (reflecting predominantly
endothelium-independent vasomotion).7 Regional MBF values from
the three major coronary artery territories on the polar map were
averaged to yield mean MBF in mL/g/min. Heart rate, blood pressure,
and a 12-lead ECG were recorded continuously during each MBF
measurement. Hyperaemic MBFs in PM were grouped into MBF
1.45 and .1.45 mL/g/min according to the flow values deviating
outside +2SD limits of normal values obtained in pre-menopausal
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women in the current study. In addition, we also defined a definitively
normal hyperaemic flow response in PM 1.98 mL/g/min based on
own previous investigations in a healthy group of pre- and post-
menopausal women.7
Statistical analysis
Data are presented as mean+ SD for quantitative and absolute fre-
quencies for qualitative variables. For comparison of differences,
appropriate t tests for independent or paired samples were used (Stat-
istical Analysis Software Institute, Cary, NC, USA). A comparison of
CPT-induced DMBF and pharmacologically induced hyperaemic MBFs
between the different groups was performed by one-way analysis of
variance (ANOVA), followed by Scheffe’s multiple comparison test.
No formal procedure was applied to account for multiple testing. Mul-
tivariable analysis was performed by means of a generalized linear
model adjusting for the following a priori selected predictors of the
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Table 1 Cross-sectional investigation: clinical characteristics, myocardial blood flow, and haemodynamics during
baseline positron emission
Young women PM with HRT P-value PM without HRT P-value
Numbers (n) 12 30 — 18 —
Age (years) 22+4 59+7 0.0001 59+8 0.0001
BMI (kg/m2) 21+1.9 27+4.9 0.0001 30+3.9 0.0001
Years of menopause — 13+6 — 11+6 —
Duration of HRT (years) — 8+5 — — —
Risk factors
Hypertension, n 0 9 (30%) — 8 (44%) —
Smoking, n 0 6 (20%) — 3 (17%) —
Hypercholesterolaemia, n 0 14 (47%) — 9 (50%) —
Obesity, n 0 7 (23%) — 9 (50%) —
Family history of CAD, n 0 11 (37%) — 4 (22%) —
Diabetes mellitus, n 0 1 (3%) — 3 (17%) —
Fasting plasma concentrations
Oestrone (ng/dL) 6.04+3.52 9.23+7.81 0.186 3.02+1.59 0.029
Oestradiol (ng/dL) 117+104 34.31+16.60 0.0001 17.80+6.70 0.001
Lipid status
Cholesterol (mg/dL) 146+17 207+38 0.0001 211+57 0.001
LDL (mg/dL) 76+17 116+39 0.0001 135+27 0.0001
HDL (mg/dL) 59+8 61+15 0.021 51+8 0.0001
TG (mg/dL) 58+27 156+68 0.0001 155+107 0.007
Glucose (mg/dL) 83+16 85+18 0.766 95+23 0.156
MBF (mL/g/min)
MBF at rest 0.66+0.14 0.68+0.15 0.687 0.73+0.18 0.213
MBF during CPT 1.00+0.24 0.92+0.30 0.334 0.89+0.17 0.191
DMBF to CPT from rest 0.35+0.23 0.24+0.20 0.171 0.16+0.12 0.021
NMBF during CPT 1.02+0.20 0.86+0.27 0.055 0.79+0.15 0.004
MBF during hyperaemia 2.47+0.51 1.66+0.29 0.0001 1.92+0.41 0.008
MFR 3.74+0.61 2.56+0.62 0.0001 2.55+0.41 0.0001
Haemodynamics
Rest-HR (b.p.m.) 62+10 66+10 0.295 67+9 0.172
CPT-HR (b.p.m.) 81+17 70+10 0.017 73+8 0.103
Hyperaemia-HR (b.p.m.) 101+13 89+14 0.020 88+10 0.015
Rest-SBP (mmHg) 101+11 126+19 0.0001 132+17 0.0001
CPT-SBP (mmHg) 124+14 154+25 0.0001 157+26 0.0001
Hyperaemia-SBP (mmHg) 107+12 127+19 0.003 129+20 0.001
Rest RPP 6275+1094 8309+1899 0.0001 8883+1717 0.0001
DRPP to CPT 3748+1969 2504+1351 0.063 2588+1859 0.120
Numbers, n (%); PM, post-menopausal women; HRT, hormone replacement therapy; CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
TG, triglyceride; CPT, cold pressor test; MBF, myocardial blood flow; MFR, myocardial flow reserve; NMBF, normalized MBF; HR, heart rate; SBP, systolic blood pressure; RPP,
rate-pressure product (HR  SBP). P-values vs. young women (t-test for independent samples).
T.H. Schindler et al.980
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Table 2 Longitudinal follow-up study: clinical characteristics, myocardial blood flow, and haemodynamics during positron emission tomography
at baseline and follow-up
Group 1 Group 2 Group 3
Baseline FU P-value Baseline FU P-value Baseline FU P-value
Numbers (n) 18 18 — 18 18 — 12 12 —
Age (years) 57+ 6 59+ 7 0.0001 59+ 8 61+ 6 0.0001 61+ 8 63+ 7 0.0001
BMI (kg/m2) 27+ 5.5 27+ 6.2 0.610 30+ 3.9 30+ 4.3 0.744 26+ 3.85 26+ 2.95 0.835
Risk factors
Hypertension, n 6 (33%) — — 8 (44%) — — 3 (25%) — —
Smoking, n 3 (17%) — — 3 (17%) — — 3 (25%) — —
Hypercholesterolaemia, n 10 (56%) — — 9 (50%) — — 4 (33%) — —
Obesity, n 5 (28%) — — 9 (50%) — — 2 (17%) — —
Family history of CAD, n 7 (39%) — — 4 (22%) — — 4 (33%) — —
Diabetes mellitus, n 0 (0%) — — 3 (17%) — — 1 (8%) — —
Fasting plasma concentrations
Oestrone (ng/dL) 10.66+ 8.48 7.69+ 5.36 0.095 3.02+ 1.59 3.24+ 1.90 0.930 7.16+ 6.55 1.61+ 1.17 0.025
Oestradiol (ng/dL) 37.14+ 17.58 29.80+ 14.44 0.125 17.80+ 6.70 19.25+ 6.54 0.238 31.55+ 16.09 15.55+ 0.93 0.019
Lipid status
Cholesterol (mg/dL) 212+ 48 213+ 40 0.980 211+ 57 214+ 32 0.946 201+ 19 204+ 36 0.787
LDL (mg/dL) 123+ 47 128+ 35 0.505 135+ 27 136+ 26 0.313 108+ 17 116+ 33 0.432
HDL (mg/dL) 60+ 17 56+ 12 0.507 51+ 8 51+ 8 0.935 63+ 11 64+ 12 0.451
TG (mg/dL) 158+76 142+ 78 0.437 155+ 107 127+ 55 0.170 152+ 59 119+ 52 0.402
Glucose (mg/dL) 85+ 9 84+ 7 0.978 95+ 23 92+ 18 0.309 85+ 25 87+ 8 0.062
MBF (mL/g/min)
Rest 0.68+ 0.16 0.73+ 0.21 0.286 0.73+ 0.18 0.78+ 0.16 0.779 0.67+ 0.14 0.70+ 0.12 0.429
CPT 0.91+ 0.32 0.92+ 0.26 0.935 0.89+ 0.17 0.83+ 0.16 0.171 0.92+ 0.29 0.67+ 0.12 0.006
DMBF to CPT 0.23+ 0.22 0.19+ 0.22 0.453 0.16+ 0.12 0.05+ 0.19 0.023 0.25+ 0.18 -0.03+ 0.14 0.001
Hyperaemia 1.69+ 0.28 1.68+ 0.40 0.616 1.92+ 0.41 1.98+ 0.44 0.146 1.62+ 0.32 1.58+ 0.32 0.332
MFR 2.62+ 0.76 2.49+ 0.98 0.655 2.55+ 0.41 2.60+ 0.62 0.779 2.46+ 0.34 2.30+ 0.56 0.426
Haemodynamics
Rest-HR (b.p.m.) 65+ 9 65+ 11 0.958 67+ 9 65+ 8 0.176 67+ 11 65+ 12 0.463
CPT-HR (b.p.m.) 70+ 10 71+ 11 0.473 73+ 8 70+ 8 0.264 71+ 11 71+ 15 0.815
Hyperaemia-HR (b.p.m.) 88+ 12 92+ 12 0.280 88+ 10 93+ 13 0.202 89+ 16 93+ 14 0.042
Rest-SBP (mmHg) 125+ 19 125+ 16 0.960 132+ 17 130+ 21 0.571 128+ 21 127+ 12 0.876
CPT-SBP (mmHg) 148+ 23 152+ 17 0.247 157+ 26 155+ 18 0.645 163+ 26 166+ 19 0.610
Hyperaemia-SBP (mmHg) 121+ 15 119+ 13 0.706 129+ 20 129+ 19 0.910 135+ 21 127+ 17 0.015
Rest-RPP 8148+ 1777 8175+ 2017 0.929 8883+ 1717 8450+ 1661 0.078 8551+ 2126 8313+ 1827 0.533
DRPP to CPT 2149+ 1132 2654+ 1099 0.082 2588+ 1859 2428+ 1028 0.743 3039+ 1523 3494+ 1180 0.131
P-values vs. corresponding baseline in each group (t-test for paired samples). Group 1: post-menopausal women (PM) with hormone replacement therapy (HRT) at baseline and follow-up (FU); group 2: PM without HRT at baseline and FU;
group 3: PM with HRT at baseline but not at FU. CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride. CPT, cold pressor test; MBF, myocardial blood flow; MFR; myocardial flow reserve;
HR, heart rate; RPP, rate-pressure product (HR x SBP).
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CPT-induced DMBF and pharmacologically induced hyperaemic MBFs:
age, body mass index (BMI), systolic blood pressure (SBP), oestrone,
oestradiol, total cholesterol, LDL cholesterol, HDL cholesterol, trigly-
cerides, and glucose. All test procedures were two-tailed, and P, 0.05
was considered statistically significant. Based on a standard deviation of
0.18 of DMBF to vasomotor stress, and a minimum clinically relevant
difference in DMBF of 0.20 in a normal and abnormal flow response,9
a ¼ 0.05, and a power (1 2 b) of 0.8, the number of patients necess-
ary for the cross-sectional baseline analysis was calculated to be 25 and
10 individuals for long-term studies.
Results
Cross-sectional study part at baseline
Clinical characteristics
Healthy young pre-menopausal women (controls, CON) had a signifi-
cantly lower BMI than PM (Table 1). Serum oestrone levels statistically
did not differ significantly between CON and PM with HRT, but were
significantly lower in PM without HRT. Serum oestradiol levels were
lower and total cholesterol, LDL cholesterol, and triglyceride levels
were higher in PM with or without HRT than in CON. In PM
without HRT, HDL cholesterol was statistically significantly lower
and total cholesterol, LDL cholesterol, and triglyceride higher than
in CON. Conversely, in PM with HRT, total cholesterol, LDL choles-
terol, and glucose tended to be lower than in PM without HRT. In
addition, HDL cholesterol levels were statistically significantly higher
in PM with HRT when compared with the group without HRT (P ¼
0.005). The years of menopause were statistically non-significant
between PM with and without HRT (P ¼ 0.093) (Table 1).
Endothelium-related myocardial blood flow responses
to cold pressor testing
Table 1 lists haemodynamic and MBF responses to vasomotor
stress in all three groups at baseline. At rest, heart rate was
similar among the groups, whereas blood pressures were statisti-
cally significantly higher in both groups of PM than in CON.
Accordingly, rate-pressure product (RPP) at rest was also higher
in PM than in CON but similar between both groups of PM. Myo-
cardial blood flows at rest tended to be lower in CON than in PM.
The group comparison of MBF at rest in controls was statistically
not significantly different from PM (P ¼ 0.373 by ANOVA).
In all three groups, sympathetic stimulation with CPT signifi-
cantly increased heart rate and SBP from rest (Table 1). The
responses of heart rate and SBP to sympathetic stimulation by
CPT were higher in CON than in the groups of PM with or
without HRT. The corresponding change of the RPP from rest
during CPT (denoted as DRPP to CPT), however, was statistically
non-significantly higher in CON than in both groups of PM, while it
was similar between the two groups of PM (Table 1). As given in
Table 1, increases in MBF from rest to CPT (DMBF to CPT) were
statistically non-significantly higher in CON than in PM with HRT
but attenuated in PM without HRT (Table 1, Figure 1A). Since the
haemodynamic response to CPT differed between CON and
PM, we normalized the MBF response to CPT to the RPP, and
thus the myocardial workload (Table 1). The normalized MBF
(NMBF) during CPT tended to be higher in CON than in PM
with HRT, although this difference did not reach statistical signifi-
cance (P ¼ 0.055) (Table 1). Compared with CON, the NMBF
during CPT was statistically significantly less in PM without HRT.
The NMBF during CPT, however, statistically did not differ signifi-
cantly between PM with HRT and PM without HRT. The group
comparison of DMBF to CPT and of NMBF during CPT in CON
was statistically significantly different from PM with and without
HRT (P, 0.037 and P, 0.036 by ANOVA, respectively). In
addition, in order to identify determinants of DMBF to CPT, a uni-
variate and multivariable analysis was performed. As demonstrated
in Table 4, only age was statistically significantly associated with the
DMBF to CPT in PM (Table 4). Further, by multivariable analysis,
oestrone and oestradiol were the only independent predictors
of the endothelium-related DMBF to CPT (Table 4), indicating
direct effects of oestrogens on coronary endothelial function.
Total hyperaemic vasodilator capacity
During pharmacologic vasodilation, the heart rate was statistically
significantly higher in CON than in PM with and without HRT,
whereas the SBP was significantly higher in both groups of PM
(Table 1). Overall, there was a definitively abnormal hyperaemic
MBF response of 1.45 mL/g/min in 21% (10/48) of PM,
whereas 29% (14/48) of PM had normal hyperaemic flow increases
of 1.98 mL/g/min. It follows then that 50% (24/48) of PM had
borderline hyperaemic MBFs of .1.45 and ,1.98 mL/g/min.
Groupwise, hyperaemic MBFs were statistically significantly
higher in CON than in PM with and without HRT (Table 1 and
Figure 1B). Moreover, they were statistically significantly lower in
PM with HRT compared with PM without HRT (P ¼ 0.039).
When the hyperaemic MBFs were related to the mean arterial
blood pressure, in order to account for differences in coronary
driving pressure, the resulting estimates of coronary vascular
resistance (CVR; mean arterial blood pressure/MBF) were statisti-
cally significantly higher in PM with and without HRT than in CON
(56+ 15 and 50+13 vs. 32+ 7 mmHg/mL/min/g, P, 0.0001,
respectively), but did not differ significantly between the both
groups of PM. The group comparison of MBF and CVR during
pharmacologic vasodilation in CON was statistically significant
when compared with both groups of PM (P, 0.0001 by
ANOVA, respectively). Finally, on univariate and multivariable
analysis, no predictors of hyperaemic MBF in response to pharma-
cologic vasodilation in PM were observed (Table 3).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Continuous concomitant cardiovascular
medication
Group 1 Group 2 Group 3
Platelet inhibitor 4 (22%) 5 (28%) 4 (33%)
Beta-blocker 3 (17%) 3 (17%) 1 (8%)
Ca-CB 2 (11%) 2 (11%) 0 (0%)
ACE-I 2 (11%) 3 (17%) 2 (17%)
Diuretic 3 (17%) 3 (17%) 2 (17%)
Statin 8 (44%) 6 (33%) 6 (50%)
Anti-diabetics 0 (0%) 0 (0%) 1 (8%)
Numbers, n; ACI, angiotensin-converting enzyme inhibitor; Ca-CB, calcium
channel blocker.
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Longitudinal study part
Clinical characteristics
At the FU, oestrone and oestradiol levels in Groups 1 and 2 had
statistically not changed significantly from baseline (Table 2). In
Group 3, however, serum oestrone and oestradiol levels declined
from baseline to FU, so that they were statistically significantly
lower at FU than in Group 1, while comparable to Group 2. In
Group 1, there was no statistically significant change in lipid
profile and plasma glucose levels during FU. Further, no statistically
significant differences in lipid profile and plasma glucose levels
were observed between baseline and FU in Groups 2 and 3. In
Group 1, PM on HRT were followed-up over a period of a
median of 22 months (IQR: 14–25). In Group 2, PM who were
not on HRT at baseline and FU, the median study period was 16
months (IQR: 14–25). Further in Group 3, PM on HRT at baseline
but not at FU had discontinued HRT after a median of 15 months
from baseline (IQR: 11–20), while the median observational study
period to FU was 28 months (IQR: 23–41). Concomitant cardio-
vascular medications are listed in Table 3. The major indication of
medical treatment was hypercholesterolaemia (14 in PM with HRT
and 9 in PM without HRT). Six PM had borderline hypercholester-
laemia not treated with statins. All cardiovascular medications had
been maintained throughout the FU period. Although treatment of
cardiovascular RFs differed between groups, the treatment in each
group was not altered between baseline and FU study.
Myocardial blood flow responses to cold pressor test
and total hyperaemic vasodilator capacity
In the FU groups, resting heart rate and SBP as well as correspond-
ing RPPs statistically did not differ significantly in repeat assess-
ments (Table 2). In addition, statistically there was no significant
change in resting MBF from baseline to FU. Cold induced a statisti-
cally significant increase in heart rate and SBP were comparable at
baseline and FU. Accordingly, the RPP, and thus cardiac work, was
similar at baseline and FU (Table 2). The DMBF in response to CPT
at FU was similar to those at baseline in Group 1, but was statisti-
cally significantly diminished in Group 2 at FU (Table 2, Figure 2A).
Importantly, the CPT-induced DMBF in Group 3 was statistically
significantly less at FU after discontinuation of HRT than at baseline
(Figure 2). The group comparison of the DMBF to CPT from rest in
Group 1 after the FU period was statistically significantly different
from Groups 2 and 3 (P, 0.0001 by ANOVA). In order to deter-
mine whether changes of the MBF response to CPT from baseline
to FU are different between groups, we compared the change in
MBF from rest to CPT (DMBF) between baseline and FU defined
as DMBF difference (DMBF at baseline2 DMBF at FU). This
DMBF difference was statistically not significantly different
between Groups 1 and 2 (20.04+0.22 vs. 20.11+ 0.19 mL/g/
min; P ¼ 0.310), but was statistically significantly reduced in
Group 3 when compared with Group 1 (20.04+0.22 vs.
20.28+0.22 mL/g/min; P ¼ 0.009). Moreover, the DMBF differ-
ence was statistically significantly greater in Group 3 than in
Group 2 (20.28+0.22 vs. 20.11+ 0.19 mL/g/min; P ¼ 0.043).
The group comparison of the difference in DMBF to CPT in
Group 1 was statistically significantly different from groups and 3
(P ¼ 0.018 by ANOVA). Further, hyperaemic MBFs were similar
at baseline and FU for all three groups (Table 2, Figure 2B). Accord-
ingly, estimates of the CVR during pharmacologic vasodilation stat-
istically did not change significantly in repeat assessments for the
three groups (Group 1: 53+13 vs. 54+ 15 mmHg/mL/min/g,
Group 2: 50+13 vs. 46+ 12 mmHg/mL/min/g, and Group 3:
60+16 vs. 58+ 12 mmHg/mL/min/g).
Discussion
The new finding of the current prospective observational investi-
gation is that HRT with oestrogen alone or in concert with a
Figure 1 (A) Change in myocardial blood flow (DMBF) from
rest in response to cold pressor testing (CPT) in young women
(controls) and in post-menopausal women (PM) with and
without hormone replacement therapy (HRT) at baseline study.
(B) Hyperaemic MBF during pharmacologic vasodilation in
young women (controls) and in PM with and without HRT at
baseline study.
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progesterone in PM, in addition to standard management of tra-
ditional cardiovascular RFs, may contribute to maintain the func-
tional integrity of vascular endothelium of the coronary
microcirculation. These observations agree with the results of pre-
vious investigations in PM without coronary RFs8 but extend the
latter observations to PM with medically treated cardiovascular
RFs.
Metabolic profile and coronary
circulatory function
At the baseline exam, total cholesterol, LDL cholesterol, and trigly-
ceride concentrations were within normal range in PM but higher
than in healthy young women, whereas HDL cholesterol levels
were lower. Further, it was observed that in PM, who had been
on HRT in the past, total cholesterol, LDL cholesterol, and
glucose tended to be lower, whereas HDL cholesterol was signifi-
cantly higher than in those PM without HRT. As the treatment with
statins was comparable between both groups, the differences in
lipoprotein fraction could be related, at least in part, to the ben-
eficial actions of HRT on lipids.10 The lipid profile and/or still unde-
termined factors in the current population of PM, however, may
account for the observed impairment of the total coronary vaso-
dilator capacity in PM. Surprisingly, on multivariate analysis, we
did not find predictors of impaired hyperaemic coronary flows in
PM possibly due to the concurrent effects of HRT, medical treat-
ment of cardiovascular RFs, and/or undetermined factors on the
arterial wall. Of particular relevance, oestrogen plasma levels did
not predict hyperaemic MBF increases in these PM with or
without HRT. The latter observations may suggest that alterations
in hyperaemic MBF increases, as indicated by previous investi-
gations,8 appear to be independent of the HRT status. Other clini-
cal investigations in the assessment of coronary vasomotor
function in PM8,11 –13 have indicated alterations in lipid profile
rather than reduced circulating oestrogen levels to account for
the altered hyperaemic coronary flow response. Notably,
current observations may also suggest that even statin-induced
cholesterol lowering associated with beneficial effects on lipids
and vasomotor function may not necessarily lead to a normaliza-
tion of diminished hyperaemic coronary flow in PM. This may
give rise to the consideration that, apart from traditional coronary
RFs, undetermined factors such as insulin resistance and/or a
complex interplay of RFs in the arterial wall may cause an impair-
ment in hyperaemic flows or predominantly vascular smooth
muscle cell function of the coronary arteriolar vessels, which
merits further investigations. Our results differ from other investi-
gations.11,14 For example, in PM with angina pectoris symptoms,
oestrogen therapy tended to increase the total coronary vasodila-
tory capacity owing to dipyridamole stimulation.11 More recently
again, the effects of 17b-oestradiol combined with the progestin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 4 Univariate and multivariable analysis in post-menopausal women implying cardiovascular risk factors
Univariate analysis Multivariable analysis
Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value
Endothelium-related DMBF to CPT
Age (years) 0.324 (0.001–0.016) 0.025 0.253 (–0.005–0.015) 0.317
BMI (kg/m2) 20.146 (20.017–0.006) 0.321 0.326 (20.004–0.024) 0.160
SBP (mmHg) 0.182 (20.001–0.005) 0.216 20.250 (20.005–0.002) 0.353
Oestrone (ng/dL) 0.066 (20.005–0.007) 0.677 21.157 (20.046–0.000) 0.047
Oestradiol (ng/dL) 0.189 (20.001–0.006) 0.238 1.479 (0.003–0.022) 0.013
Total cholesterol (mg/dL) 20.205 (20.002–0.000) 0.176 21.599 (20.028–0.015) 0.547
LDL cholesterol (mg/dL) 20.244 (20.003–0.000) 0.115 1.886 (20.014–0.030) 0.472
HDL cholesterol (mg/dL) 0.100 (20.003–0.006) 0.517 1.049 (20.012–0.031) 0.373
Triglycerides (mg/dL) 20.031 (20.001–0.001) 0.843 0.574 (20.003–0.005) 0.591
Glucose (mg/dL) 0.081 (20.002–0.003) 0.604 0.312 (20.001–0.005) 0.144
Hyperaemic MBF during pharmacologic vasodilation
Age (years) 0.151 (20.008–0.023) 0.328 20.381 (20.050–0.012) 0.218
BMI (kg/m2) 20.087 (20.029–0.017) 0.576 20.382 (20.077–0.016) 0.180
SBP (mmHg) 0.281 (0.000–0.011) 0.065 0.398 (20.002–0.017) 0.135
Oestrone (ng/dL) 20.135 (20.029–0.012) 0.418 20.199 (20.083–0.062) 0.761
Oestradiol (ng/dL) 20.166 (20.011–0.004) 0.327 20.083 (20.032–0.028) 0.900
Total cholesterol (mg/dL) 0.226 (20.001–0.004) 0.156 0.944 (20.057–0.077) 0.764
LDL cholesterol (mg/dL) 20.010 (20.003–0.003) 0.953 21.079 (20.079–0.056) 0.728
HDL cholesterol (mg/dL) 0.037 (20.007–0.009) 0.821 20.318 (20.072–0.058) 0.819
Triglycerides (mg/dL) 0.193 (20.001–0.002) 0.240 20.268 (20.014–0.011) 0.823
Glucose (mg/dL) 0.008 (20.006–0.006) 0.963 20.028 (20.010–0.009) 0.912
P-values by analysis of variance; MBF, myocardial blood flow; BMI, body mass index; SBP, systolic blood pressure; LDL cholesterol, low-density lipoprotein cholesterol; HDL
cholesterol, high-density lipoprotein cholesterol.
T.H. Schindler et al.984
drospirenone on hyperaemic MBFs in symptomatic PM were
studied. Post-menopausal women did not have type 2 diabetes
mellitus or hyperlipidaemia, while some were smokers and
others were medically treated for arterial hypertension.14 In a
double-blind randomized study protocol, however, a 6-week FU
with 17b-oestradiol and drospirenone did lead to a mild but stat-
istically significant improvement in hyperaemic MBFs and the cor-
responding myocardial flow reserve when compared with a
placebo group.14 The reason for the contradictory observations
of a beneficial effect of HRT on hyperaemic MBFs in PM8,12,14
remains uncertain but is likely multifactorial. Differences in the
clinical characteristics of PM studied,8,12,14 differences in the dur-
ation of the post-menopause, differences in the state of altered
vascular smooth muscle cell and/or endothelial function, differ-
ences in structural alterations in the myocardium, and/or differ-
ences in the use of progestins combined with oestrogens10 are
likely to account for the observed contrasting effects of HRT on
hyperaemic MBFs.
In the assessment of coronary vasomotor function, MBF
responses to sympathetic stimulation with CPT have been shown
to provide specific information on the endothelium-dependent
vasomotion of the coronary microcirculation.7 In the current
study, the cross-sectional comparison of MBF responses to vaso-
motor stress at baseline yielded comparable endothelium-related
flow increases to cold exposure between PM with HRT and
healthy young women, whereas the endothelium-related flow
responses were significantly diminished in PM without HRT. The
latter observations may indeed suggest that HRT therapy benefi-
cially affects endothelial function of the coronary microcirculation
in PM, even when RFs were treated by medical intervention. As
endothelial dysfunction in PM is considered as an independent pre-
dictor of subsequent cardiovascular events,7 coronary microcircu-
latory dysfunction in PM may emerge as a specific target for HRT
to improve the cardiovascular outcome.15 Confounding effects of
the lipid profile, medical treatment of RFs, and/or undetermined
factors, however, are likely to have also altered endothelial func-
tion of the coronary arteriolar vessels apart from HRT. On multi-
variate analysis, however, oestrogen plasma levels were indeed
independent predictors of the endothelium-related MBF response
to CPT. With regard to the effects of HRT on coronary vasomotor
function, current observations provide direct evidence that oestro-
gen concentrations, in addition to standard management of tra-
ditional RFs, may exert beneficial effects on endothelium-related
microvascular function. Further support of this comes from the
observational longitudinal FU investigations in the current study
population. At FU, the endothelium-related MBF response to
CPT in PM with treated RFs and with HRT had remained
unchanged, but had further declined in those PM without HRT.
Notably, while at baseline, endothelium-related flow increases to
CPT were maintained in PM with HRT when compared with
young women, the flow response to CPT had only declined in
those PM who had not pursuit HRT during the FU. In addition,
the endothelium-related MBF response to CPT in PM who had dis-
continued HRT was worse than in those PM who had never been
on HRT. The underlying mechanism for the ‘rebound’ phenom-
enon on coronary vascular function remains uncertain but it is
possible that discontinuation of HRT may have conferred an
enhanced adverse effect on the coronary endothelium similar to
the one that has been described for statin withdrawal.16
As 40–50% of PM were on HRT with oestrogen plus a pro-
gesterone, however, it is equally possible that progestins had
affected endothelium vasomotor function. Unlike as in subhuman
primates,17 progestin application in PM did not negate the ben-
eficial effect of oestrogen on endothelial function of the coronary
and peripheral circulation.8 The reason for this discrepant obser-
vation is unclear, but is likely to be related to differences in metab-
olites of progestational substances comprising MPA specific to
subhuman primates,8 which might account for adverse effects on
endothelial function.
Since functional abnormalities of the coronary circulation in PM,
associated with pro-atherosclerotic and pro-thrombotic effects,7
may reflect an important mechanistic link between coronary vaso-
motor dysfunction and cardiovascular outcome, the beneficial
Figure 2 (A) The endothelium-related change in myocardial
blood flow (DMBF) from rest to cold pressor testing (CPT) at
baseline and follow-up (FU) in Groups 1–3. (B) Hyperaemic
MBF during pharmacologic vasodilation in Groups 1–3 of post-
menopausal women at baseline and at FU.
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effect of long-term HRT on endothelium-dependent coronary
microvascular function, as observed in the current study and by
other investigations,8,18 may agree with improved cardiovascular
outcome of HRT in younger PM from the overall WHI-CEE trial
analysis,4 and, as reported recently, when HRT was initiated
between the ages of 50 and 59 years or within 10 years after
menopause.19 Post-menopausal women in the current study
were mostly between 50 and 59 years of age and, thus, relatively
young. Thus, the observations of the beneficial effect of HRT on
endothelium-dependent coronary microvascular function may
indeed accord with the ‘timing hypothesis’ for HRT. According
to the latter, a benefit of HRT in preventing the CAD process
may manifest when HRT is started before advanced stages of
atherosclerosis are present.2 And indeed, a beneficial effect of
HRT on flow-mediated brachial artery function was predominantly
observed in PM in their 50s, which appeared also to be affected by
the time period since menopause.18
Limitations
There are limitations worthy to be considered in interpreting the
current study data. The current study did not assess the molecular
mechanism underlying the beneficial effect of HRT on
endothelium-dependent vasomotion of the coronary microcircula-
tion. Future experimental studies may further elucidate the role of
various components of HRT in determining the mechanism of ben-
eficial effects on coronary endothelial function. Also, because all
women were asymptomatic and had normal PET perfusion
imaging at rest and hyperaemic stress, arguing against the presence
of flow-limiting epicardial lesions, the use of coronary angiography
and intravascular ultrasound was not deemed ethically justified and,
thus, it was not performed. This again means that we do not know
whether PM had none or early stages of subclinical CAD, which
might have affected the vasomotor response to HRT. Finally, in
view of the relatively small sample size of the study population
and the observational study design with its inherent limitations
such as a possible selection bias, the lack of randomization of
study participants to HRT at baseline inclusion, the presence of
confounding cardiovascular RFs in concert with their medical treat-
ment, and the absence of an objective criteria to continue or inter-
rupt HRT, the current study does certainly not permit definite
conclusions but may contribute to stimulate further large-scale,
randomized clinical investigations of the effects of HRT on vaso-
motor function in PM and its clinical outcome.
Conclusions
Long-term administration of oestrogen may exert beneficial effects
on endothelium-dependent vasomotion of the coronary micro-
circulation in PM with treated cardiovascular RFs and without
clinical CAD.
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